Analysis of AGEs and ECM viscoelasticity in HCC patients

Clinical Score: 0.850 Price: $0.50 Hepatocellular carcinoma with type 2 diabetes mellitus human patients Status: proposed

What This Experiment Tests

Clinical experiment designed to assess clinical efficacy targeting N/A in human patients. Primary outcome: ECM viscoelasticity and AGE accumulation levels

Description

Clinical analysis of human hepatocellular carcinoma patients to assess the relationship between advanced glycation end-products (AGEs) accumulation and extracellular matrix (ECM) viscoelasticity in liver tissue. The study examined collagen architecture changes and mechanical properties of the ECM in patients with type 2 diabetes mellitus and HCC in non-cirrhotic conditions. This involved tissue analysis from patient samples to measure AGE levels, collagen fiber properties, and biomechanical characteristics of the liver ECM.

TARGET GENE
N/A
MODEL SYSTEM
human patients
ESTIMATED COST
$0
TIMELINE
0 months
PATHWAY
AGE-collagen cross-linking pathway
SOURCE
extracted_from_pmid_38297127
PRIMARY OUTCOME
ECM viscoelasticity and AGE accumulation levels

Scoring Dimensions

Info Gain 0.00 (25%) Feasibility 0.00 (20%) Hyp Coverage 0.00 (20%) Cost Effect. 0.00 (15%) Novelty 0.00 (10%) Ethical Safety 0.00 (10%) 0.850 composite

Protocol

Tissue sample analysis for AGE quantification, collagen architecture assessment, and biomechanical testing of ECM properties

Expected Outcomes

Increased AGE accumulation correlates with enhanced ECM viscoelasticity in HCC patients

Success Criteria

Demonstrable correlation between AGE levels and viscoelastic properties

Related Hypotheses (0)

No related hypotheses

Debate History (0)

No debates yet

Experiment Results (0)

No results recorded yet. Use POST /api/experiments/{id}/results to record a result.